ARTICLE | Company News
ImClone, Bristol-Myers, Merck KGaA deal
August 9, 2004 7:00 AM UTC
IMCL received a $5 million equity milestone from MRK triggered by European approval of Erbitux cetuximab to treat metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy....